MBC Advocate
@mbcadvocate
MBC Advocate, following MBC breakthroughs
ID: 1585930982334636032
28-10-2022 09:47:58
3,3K Tweet
1,1K Takipçi
840 Takip Edilen
TransCode Therapeutics has announced the dosing of the first two patients in its Phase 1 multi center clinical trial for TTX-MC138, a first-in-class therapeutic candidate designed to treat metastatic cancers. $RNAZ #ESMO24 OncoAlert ESMO - Eur. Oncology #MBC #bcsm stocktitan.net/news/RNAZ/tran…